Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. On our course to eradicate cancer we will develop new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.

  • Clinical trials are in progress to demonstrate the feasibility of providing prophylactic vaccines that prevent cancer.
  • Partnerships are formed to collaboratively established the viability of early cancer diagnosis.
  • FAST vaccine trials are being initiated that could dramatically reduce the time and expense of cancer treatments.

Team

STEPHEN ALBERT JOHNSTON

Founder, CEO

Stephen Albert Johnston is the inventor of the Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics),Synbody Biotechnology and HealthTell, Inc. (iCarbonX). He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.

KATHRYN SYKES, PH.D

VP Research & Product Development

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

DOUGLAS THAMM DVM, PH.D.

Head of Clinical Research

Dr. Thamm is a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. He has authored over 115 peer-reviewed publications and 20 book chapters as well is editor for prominent veterinary journals.His interests include novel targeted therapies for cancer. Thamm received his degrees from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin.

TERRENCE O’NEIL

Director or Production

Terrence O’Neil has over 20 years of experience in multiple industries including Biotechnology, Manufacturing, Retail, and Banking. He is an accomplished leader with an outstanding record of success in project management, strategic planning, program development, organizational management. At HealthTell he served the role of Manager of Operations and provided strong leadership to scale-up operations in this early stage company. He increased his responsibility as Director of Program Management at iCarbonX, Inc. Previously, he held management positions at multiple Fortune 50 companies. Mr. O’Neil received his B.A. in Biochemistry from Arizona State University.

EDWARD RADY

Head of Business Development

Edward Rady has broad experience in healthcare businesses, including 15 years in major Pharma, 12 years as a company founder and entrepreneur in medical education, 5 years as CEO of the largest heathcare communications company in the world, and successfully founded 3 consulting companies. Proven record of success. A quick study, skilled in creating a strategic vision, negotiating a position, simplifying and communicating complex issues. Guided by a big picture focus but a passion for the details.

Board of Directors

STEPHEN ALBERT JOHNSTON

Stephen Albert Johnston is the inventor of the Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics),Synbody Biotechnology and HealthTell, Inc. (iCarbonX). He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.

JACQUE SOKOLOV, M.D.

Dr. Sokolov is chairman and chief executive officer of SSB Solutions, Inc., a US based and diversified healthcare management, development and financial services company. Following his formal training as an academic cardiologist, He started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation. Dr. Sokolov currently serves or has served in multiple board capacities for Public Companies including Hospira, MedCath, and PhyAmerica; Private Companies including Veterans Accountable Care Group, GlobalMed, SMG Holding Company, MyHealthDirect, NeuLife Neurological Services, LLC, IntelaTrak, PCA Holdings and SSB Solutions/HCDG; and Non Profit Organizations including Phoenix Children’s Hospital and numerous others. Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School.

KATHRYN SYKES, PH.D

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

MICHAEL CHAMBERS

Michael Chambers co-founded Aldevron in 1998, holding the position of President and CEO until this year. He is now Chairman of its Board. Using a technology platform that he co-invented, Aldevron started producing plasmid DNA for biotech researchers in a small lab on the campus of North Dakota State University (NDSU) in Fargo, ND. He and his co-founder built what is today considered the industry’s leading and most respected contract manufacturing organizations in the world. The company utilizes industry-enabling technologies to make recombinant products including nucleic acids, gene editing enzymes, proteins and antibodies. Exemplifying ongoing success, an additional manufacturing plant of 190,000 square-feet building is under construction. In recognition of his significant contributions to the industry, Chambers was named as one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs in 2018. He received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from NDSU.

Investors

CALVIRI is seeking Series A funding for infrastructure, R&D, and operations to enable multiple clinical trials in dogs and humans. We thank our current seed investors for their support.

Learn More About Investing

investors-new5

Investors

CALVIRI is seeking series A funding for infrastructure, R&D, and operations to enable multiple clinical trials in dogs and humans. We thank our current investors for their support.

  • FAST Therapeutic Vaccine
  • Early Detection
  • Responders vs. Non-Responders
  • Antibody-based
  • Highly Sensitive
  • Inexpensive & Simple
  • New Market
  • Shared Neoantigens
  • Preventative Cancer Vaccine